文献速递心脑血管急症重症综合管理与镇静镇痛

氟哌啶醇与非典型抗精神病药在急性心肌梗死患者中的院内死亡风险比较:队列研究

Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.
PubMed 文献 · BMJ · 2018-03-28
一句话结论急性心肌梗死患者起始口服氟哌啶醇较非典型抗精神病药7天内死亡风险约增50%(调整HR 1.50),风险主要集中在前4天。

这项基于美国700余家医院数据库的队列研究纳入6578例因急性心肌梗死入院并起始口服氟哌啶醇或口服非典型抗精神病药(奥氮平、喹硫平、利培酮)的成年患者,比较起始治疗后7天内院内死亡风险。经1:1倾向评分匹配后,氟哌啶醇组7天内每100人日死亡率为1.7(129例死亡),非典型抗精神病药组为1.1(92例死亡);调整后死亡风险比为1.50(95%CI 1.14–1.96)。该关联在随访前4天最强,至第5天不再明显(HR 1.12,95%CI 0.79–1.59)。作者认为,在因心脏疾病入院患者中使用氟哌啶醇时,这一发现值得考虑。

要点

  • 急性心肌梗死患者起始口服氟哌啶醇较口服非典型抗精神病药(奥氮平、喹硫平、利培酮)7天内死亡风险升高,调整HR 1.50(95%CI 1.14–1.96)。
  • 匹配队列中7天内每100人日死亡:氟哌啶醇组1.7(129例死亡) vs 非典型抗精神病药组1.1(92例死亡)。
  • 风险随时间衰减:前4天关联最强,至第5天不再明显(HR 1.12,95%CI 0.79–1.59)。
  • 按实际治疗分析中,未调整与调整HR分别为1.90(1.43–2.53)和1.93(1.34–2.76)。
  • 作者认为,虽然不能排除残余混杂,但在因心脏疾病入院患者中使用氟哌啶醇时,这一发现值得考虑。

适用人群与场景

  • 2003至2014年间因急性心肌梗死(主要诊断)入院、年龄大于18岁的内科患者,住院期间起始口服氟哌啶醇或口服非典型抗精神病药(奥氮平、喹硫平、利培酮)。
  • 数据来自美国700余家医院的全国性患者样本数据库。

研究设计与关键结果

  • 研究类型为基于医疗保健数据库的队列研究,纳入6578例患者(平均年龄75.2岁),其中1668例(25.4%)起始氟哌啶醇,4910例(74.6%)起始非典型抗精神病药。
  • 入院至起始治疗平均时间(5.3 vs 5.6天)和住院时间(12.5 vs 13.6天)两组相近,但氟哌啶醇组平均治疗时长较短(2.4 vs 3.9天)。
  • 采用1:1倾向评分匹配调整混杂;意向治疗分析中,起始治疗后7天随访内每100人日死亡绝对率:氟哌啶醇组1.7(129例死亡) vs 非典型抗精神病药组1.1(92例死亡)。
  • 第7天生存概率:氟哌啶醇组0.93 vs 非典型抗精神病药组0.94(已考虑因出院导致的失访)。
  • 未调整和调整后死亡风险比分别为1.51(95%CI 1.22–1.85)和1.50(95%CI 1.14–1.96)。
  • 关联在随访前4天最强,随时间下降;至第5天风险升高不再明显(HR 1.12,95%CI 0.79–1.59)。
  • 按实际治疗分析中,未调整和调整后风险比分别为1.90(95%CI 1.43–2.53)和1.93(95%CI 1.34–2.76)。

证据类型、等级与局限

  • 证据类型:基于医疗保健数据库的队列研究。
  • 原文指出不能排除残余混杂(residual confounding cannot be excluded)。

对床旁实践的改变

  • 作者认为,在因心脏疾病入院患者中使用氟哌啶醇时,这一发现值得考虑。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare the risk of in-hospital mortality associated with haloperidol compared with atypical antipsychotics in patients admitted to hospital with acute myocardial infarction.

DESIGN: Cohort study using a healthcare database.

SETTING: Nationwide sample of patient data from more than 700 hospitals across the United States.

PARTICIPANTS: 6578 medical patients aged more than 18 years who initiated oral haloperidol or oral atypical antipsychotics (olanzapine, quetiapine, risperidone) during a hospital admission with a primary diagnosis of acute myocardial infarction between 2003 and 2014.

MAIN OUTCOME MEASURE: In-hospital mortality during seven days of follow-up from treatment initiation.

RESULTS: Among 6578 patients (mean age 75.2 years) treated with an oral antipsychotic drug, 1668 (25.4%) initiated haloperidol and 4910 (74.6%) initiated atypical antipsychotics. The mean time from admission to start of treatment (5.3 v 5.6 days) and length of stay (12.5 v 13.6 days) were similar, but the mean treatment duration was shorter in patients using haloperidol compared with those using atypical antipsychotics (2.4 v 3.9 days). 1:1 propensity score matching was used to adjust for confounding. In intention to treat analyses with the matched cohort, the absolute rate of death per 100 person days was 1.7 for haloperidol (129 deaths) and 1.1 for atypical antipsychotics (92 deaths) during seven days of follow-up from treatment initiation. The survival probability was 0.93 in patients using haloperidol and 0.94 in those using atypical antipsychotics at day 7, accounting for the loss of follow-up due to hospital discharge. The unadjusted and adjusted hazard ratios of death were 1.51 (95% confidence interval 1.22 to 1.85) and 1.50 (1.14 to 1.96), respectively. The association was strongest during the first four days of follow-up and decreased over time. By day 5, the increased risk was no longer evident (1.12, 0.79 to 1.59). In the as-treated analyses, the unadjusted and adjusted hazard ratios were 1.90 (1.43 to 2.53) and 1.93 (1.34 to 2.76), respectively.

CONCLUSION: The results suggest a small increased risk of death within seven days of initiating haloperidol compared with initiating an atypical antipsychotic in patients with acute myocardial infarction. Although residual confounding cannot be excluded, this finding deserves consideration when haloperidol is used for patients admitted to hospital with cardiac morbidity.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018. PMID: 29592958. doi:10.1136/bmj.k1218

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。